Apremilast relieved psoriatic arthritis symptoms in phase 3 study

Apremilast relieved psoriatic arthritis symptoms in phase 3 study

At week 16, 93% of patients completed the trial, with comparable rates of completion between the treatment groups and placebo group. Significantly more patients who received 20-mg or 30-mg apremilast achieved an ACR20 response rate, with 28% of …

(Visited 5 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.